Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate [sunitinib] Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma

Next Previous
Trial Profile

A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate [sunitinib] Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunitinib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 01 Apr 2022 Results assessing a clinical prediction tool for predicting severe hand-foot syndrome published in the Cancer Chemotherapy and Pharmacology
    • 26 Mar 2022 This trial has been completed in Belgium (End Date: 08 Dec 2011), according to European Clinical Trials Database record.
    • 28 Sep 2020 Results evaluating the impact of PPI use on the survival outcomes of advanced HCC patients treated with sorafenib published in the Journal of Cancer Research and Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top